Literature DB >> 11768035

Cognitive effects of standard-dose chemotherapy in patients with cancer.

T A Ahles1, A Saykin.   

Abstract

Adult cancer survivors have reported experiencing persistent changes in cognitive function following treatment with chemotherapy. Increasing evidence supports the hypothesis that standard-dose chemotherapy can produce cognitive deficits in a subgroup of adult cancer survivors. Although these cognitive changes tend to be subtle deficits in memory, concentration, and the ability to remain focused or organized, these alterations in cognitive ability can have a significant impact on patients' quality of life generally, and on meeting career and educational goals specifically. This manuscript reviews the literature relevant to the cognitive impact of standard-dose chemotherapy in adults, outlines methodological issues related to the study of cognitive functioning in people with cancer, and discusses future directions for research in this area.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11768035     DOI: 10.1081/cnv-100107743

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  48 in total

1.  Clinical predictors of cognitive function in adults treated with hematopoietic cell transplantation.

Authors:  Heather S L Jim; Brent Small; Sheri Hartman; Jamie Franzen; Shannon Millay; Kristin Phillips; Paul B Jacobsen; Margaret Booth-Jones; Joseph Pidala
Journal:  Cancer       Date:  2011-12-02       Impact factor: 6.860

Review 2.  What is known and unknown about chemotherapy-related cognitive impairment in patients with haematological malignancies and areas of needed research.

Authors:  Annalynn M Williams; Clive S Zent; Michelle C Janelsins
Journal:  Br J Haematol       Date:  2016-07-08       Impact factor: 6.998

3.  Development of CBT for chemotherapy-related cognitive change: results of a waitlist control trial.

Authors:  Robert J Ferguson; Brenna C McDonald; Michael A Rocque; Charlotte T Furstenberg; Susan Horrigan; Tim A Ahles; Andrew J Saykin
Journal:  Psychooncology       Date:  2010-12-02       Impact factor: 3.894

4.  Potential factors associated with perceived cognitive impairment in breast cancer survivors.

Authors:  Jamie S Myers; Jo A Wick; Jennifer Klemp
Journal:  Support Care Cancer       Date:  2015-04-03       Impact factor: 3.603

Review 5.  Neurocognitive functioning and genetic variation in patients with primary brain tumours.

Authors:  Jeffrey S Wefel; Kyle R Noll; Michael E Scheurer
Journal:  Lancet Oncol       Date:  2016-03-02       Impact factor: 41.316

6.  Understanding the Profile of Cancer-Related Cognitive Impairments: A Critique of Meta-Analyses.

Authors:  Todd S Horowitz; Melissa Treviño; Ingrid M Gooch; Korrina A Duffy
Journal:  J Natl Cancer Inst       Date:  2019-10-01       Impact factor: 13.506

Review 7.  Central nervous system toxicity from cancer treatment.

Authors:  Terri Armstrong; Mark R Gilbert
Journal:  Curr Oncol Rep       Date:  2004-01       Impact factor: 5.075

8.  Genetic and environmental mediation of the associations between self-rated health and cognitive abilities.

Authors:  Pia Svedberg; Margaret Gatz; Nancy L Pedersen
Journal:  Exp Aging Res       Date:  2009 Apr-Jun       Impact factor: 1.645

Review 9.  Cognitive effects of cytotoxic cancer chemotherapy: predisposing risk factors and potential treatments.

Authors:  Thomas W McAllister; Tim A Ahles; Andrew J Saykin; Robert J Ferguson; Brenna C McDonald; Lionel D Lewis; Laura A Flashman; C Harker Rhodes
Journal:  Curr Psychiatry Rep       Date:  2004-10       Impact factor: 5.285

10.  Cognitive speed of processing and functional declines in older cancer survivors: an analysis of data from the ACTIVE trial.

Authors:  E A Kvale; O J Clay; L A Ross-Meadows; J S McGee; J D Edwards; F W Unverzagt; C S Ritchie; K K Ball
Journal:  Eur J Cancer Care (Engl)       Date:  2009-08-26       Impact factor: 2.520

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.